Clinical Report: Stuart Therapeutics Expands Corneal Repair Pipeline

Overview

Stuart Therapeutics submitted an IND amendment to the FDA to study ST-100 (vezocolmitide) for corneal wound healing, extending its development program beyond dry eye disease. The planned proof-of-concept study will assess epithelial and stromal repair after corneal injury; efficacy for this indication has not been established.

Background

Corneal wounds may result from surgery, trauma, ulcers, chemical burns, or recurrent corneal erosion. The company describes ST-100 as a collagen mimetic peptide developed with its PolyCol technology and designed to target damaged helical collagen in the ocular extracellular matrix. Current options were characterized by a company spokesperson and a clinician quoted in the announcement as supporting the eye during healing rather than directly repairing this collagen structure. The proposed program will test whether ST-100 can support repair after injury.

Data Highlights

Key Findings

• ST-100 is described as a collagen mimetic peptide developed using Stuart Therapeutics' PolyCol technology platform.
• The proposed proof-of-concept study is the company's first expansion of ST-100 beyond dry eye disease and will evaluate epithelial and stromal repair following corneal injury.
• The company intends to follow the initial study with a phase 2 trial in the second half of 2027, covering wounds associated with surgery, trauma, ulcers, and chemical burns.
• Across phase 2 and initial phase 3 dry eye disease studies involving more than 250 patients, the company reported improvements in corneal fluorescein staining and several symptom-related outcomes; some benefits were observed as early as two days.
• The initial phase 3 dry eye disease trial did not meet its primary endpoint of statistically significant improvement in Schirmer's tear test responder rates compared with vehicle.
• ST-100's efficacy for corneal wound healing remains to be established; the announcement describes the proposed studies as a means of evaluating the approach.

Clinical Implications

The proposed study will provide clinical evidence on whether ST-100 supports epithelial and stromal repair after corneal injury. The source does not report established efficacy for this indication, and the initial phase 3 dry eye disease trial did not meet its primary endpoint.

Conclusion

Stuart Therapeutics is extending ST-100 development to corneal wound healing, with a proof-of-concept study planned and a phase 2 trial intended for the second half of 2027. Whether the candidate can repair damaged corneal collagen or improve healing remains to be determined.

Related Resources & Content

1. Stuart Therapeutics, Stuart Therapeutics, 2026 -- Stuart Therapeutics Expands Pipeline with Corneal Wound Healing Program
2. Optometric Management, 2026 -- Stuart Therapeutics Expands Pipeline With Corneal Wound Healing Program
3. Ophthalmology Management, 2026 -- Stuart Expands Pipeline With Corneal Wound Healing Program
4. Optometric Management — Stuart Therapeutics Expands Pipeline With Corneal Wound Healing Program Recommendations
5. the ophthalmologist — Stuart Therapeutics, Inc. Appoints Dave LeCause as Senior Commercial Advisor
6. Stuart Therapeutics Expands Pipeline with Corneal Wound Healing Program
7. Stuart Therapeutics Expands Pipeline With Corneal Wound Healing Program
8. Stuart Expands Pipeline With Corneal Wound Healing Program
9. BCSC2026-27_S08_C01_p001_016_3P.indd
10. Medical and surgical interventions for neurotrophic keratopathy - PubMed
11. Stuart Therapeutics Expands Pipeline with Corneal Wound Healing Program – Stuart Therapeutics